During a routine ambulatory visit, a 58-year-old male is evaluated for ongoing management … — USMLE Step 3

During a routine ambulatory visit, a 58-year-old male is evaluated for ongoing management of type 2 diabetes mellitus and hypertension. Eight weeks prior, his primary care provider initiated high-intensity cardiovascular risk reduction therapy with rosuvastatin. The patient states he feels well and specifically denies experiencing new-onset muscle pain, weakness, dark urine, or abdominal discomfort. His current medication regimen includes metformin, lisinopril, and rosuvastatin. His blood pressure is $128/78 \text{ mmHg}$ , and his heart rate is $72\text{/min}$ . Physical examination reveals no scleral icterus, right upper quadrant tenderness, or muscle weakness.

Laboratory studies obtained today show the following:

Test	Result	Reference Range
Aspartate aminotransferase (AST)	$75 \text{ U/L}$	$10-40 \text{ U/L}$
Alanine aminotransferase (ALT)	$90 \text{ U/L}$	$10-40 \text{ U/L}$
Creatine kinase (CK)	$110 \text{ U/L}$	$55-170 \text{ U/L}$
Total bilirubin	$0.8 \text{ mg/dL}$	$0.1-1.2 \text{ mg/dL}$

Baseline liver function tests prior to starting rosuvastatin were within normal limits.

Which of the following is the most appropriate next step in the management of this patient's medication regimen?

Maintain current rosuvastatin therapy and provide reassuranceCevap
B
Continue rosuvastatin and add gemfibrozil to optimize the lipid profile
C
Discontinue rosuvastatin and order a comprehensive viral hepatitis panel
D
Continue current medications and order a right upper quadrant abdominal ultrasound
E
Decrease the rosuvastatin dose by half and schedule a liver biopsy

Cevap

Maintain current rosuvastatin therapy and provide reassurance.

The correct action involves continuing the statin without modification. Statin therapy frequently causes asymptomatic, dose-dependent elevations in hepatic transaminases. Current management guidelines explicitly state that if aminotransferase levels are elevated but remain less than 3 times the upper limit of normal (ULN) and the patient is asymptomatic, the statin should be continued without dose reduction. In this scenario, the patient's AST and ALT are roughly twice the ULN, he lacks symptoms of hepatotoxicity or myopathy, and his bilirubin is normal. Therefore, reassurance and continuation of evidence-based therapy is the standard of care.

Adım Adım Çözüm

Evaluate the patient's clinical presentation and laboratory results.

The patient is completely asymptomatic with mild transaminase elevations (AST

75 \text{ U/L}

, ALT

90 \text{ U/L}

, both strictly <3x the upper limit of normal) and a normal creatine kinase (CK) level.

To determine the severity of potential statin-induced hepatotoxicity or myopathy before altering the treatment plan.

Apply clinical guidelines for statin monitoring and treatment evaluation.

Current guidelines indicate that asymptomatic elevations of transaminases <3x ULN do not require statin discontinuation, dose adjustment, or extensive diagnostic workup.

Mild hepatic enzyme elevation is a known, dose-dependent, and usually benign effect of statin therapy that often resolves or stabilizes on its own.

Formulate the optimal management plan.

Continue the current dose of rosuvastatin and reassure the patient.

The established cardiovascular mortality benefits of high-intensity statin therapy in a diabetic patient far outweigh the negligible risks associated with mild, asymptomatic transaminitis.

Anahtar Kavram

Management of statin-associated hepatic enzyme elevations

Tahmini Süre:1m 15s

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru